
## **Supplementary Table 1.** Search strategy used in the various databases

Database	Search terms						
PubMed	((liver cancer[MeSH Terms]) OR ((hepatocellular carcinoma[MeSH Terms]) OR (liver cell carcinoma, adult[MeSH Terms])) OR hepatocellular carcinoma) AND ((treatment delay[MeSH Terms]) OR (time to treatment[MeSH Terms]) OR treatment timing OR delayed treatment OR waiting time)						
Embase	('liver cell carcinoma'/exp) AND (('time to treatment'/exp) OR ('therapy delay'/exp))						
Scopus	TITLE-ABS-KEY (("hepatocellular carcinoma" OR "liver cell carcinoma" OR "HCC" OR "liver cell cancer") AND ("time to treatment" OR "delayed treatment" OR "treatment delay"))						
The Cochrane Library	((MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees) OR ("hepatocellular carcinoma" OR 'liver cell carcinoma' OR 'HCC'):ti,ab,kw) OR ((MeSH descriptor: [Time-to-Treatment] explode all trees) OR ('treatment delay' OR 'delayed treatment' OR 'time interval' OR 'treatment timing'):ti,ab,kw)						

Supplementary Table 2. Modified Newcastle–Ottawa score of all included studies

First author	Selection				Compar- ability	Outcome			
	Represen- tativeness of exposed cohort	Selection of non- exposed cohort	Ascertain- ment of exposure	Demon- stration that outcome of interest was not present at start of study	Compar- ability of cohorts based on basis of design or analysis	Assess- ments of outcomes	Was follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	Total <sup>a)</sup>
Xu et al. [3]	1	1	1	1	2	1	1	0	8
Wagle et al. [13]	1	1	1	1	1	1	1	1	8
Tsilimigras et al. [5]	1	1	1	1	2	1	1	0	8
Tsai et al. [15]	1	1	1	1	1	1	1	1	9
Singal et al. [22]	1	1	1	1	1	1	1	0	7
Rao et al. [6]	1	1	1	1	1	1	1	0	7
Ong et al. [19]	1	1	1	1	1	1	1	1	7
Lim et al. [18]	1	1	1	1	2	1	1	1	9
Kabir et al. [4]	1	1	1	1	2	1	1	1	9
Huo et al. [17]	1	1	1	1	2	1	1	1	9
He et al. [16]	1	1	1	1	2	1	1	0	6
Govalan et al. [7]	1	1	1	1	2	1	1	0	8
Chen et al. [21]	1	1	1	1	1	1	1	0	7
Brahmania et al. [20]	1	1	1	1	2	1	1	1	9

<sup>&</sup>lt;sup>a)</sup>Quality score of < 3: low quality of evidence, 3–6: moderate quality of evidence,  $\ge 7$ : high quality of evidence.



**Supplementary Fig. 1.** Funnel plots of the included studies (A) OS, (B) disease-free survival, (C) OS in subgroup of patients with time-to-treatment cut-off defined as 90 d, and (D) OS within subgroup of patients who received liver resection only. OS, overall survival; SE, standard error.